公开(公告)号：US20210169928A1

公开(公告)日：2021-06-10

申请号：US16936090

申请日：2020-07-22

申请人： EriVan Bio, LLC

发明人： Nasrin Nassiri Koopaei ,  Jeffrey L. Tate

IPC分类号： A61K35/15 ,  A61K31/506 ,  A61K31/721 ,  A61K45/06

摘要： Topical exosome compositions for treating a variety of conditions in a subject, including methods of making and using the same. Exemplary embodiments employ MSC exosomes and secretome as components of the compositions, including but not limited to A-MSC exosomes and secretome.

公开(公告)号：US11026972B2

公开(公告)日：2021-06-08

申请号：US16156146

申请日：2018-10-10

申请人： Georgia State University Research Foundation, Inc.

发明人： Yuan Liu ,  Zhen Bian ,  Ke Zen

IPC分类号： A61K35/15 ,  A61K31/739 ,  A61K38/19 ,  A61K45/06 ,  C07K16/24 ,  A61K39/395 ,  A61K38/20 ,  A61K31/7088 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0786 ,  C12N15/113 ,  A61K39/00

摘要： The present invention relates to compositions and methods variously useful in treating cancer, inhibiting graft rejection, and treating autoimmune disease. The compositions and methods include those in which macrophages are conditioned to down regulate or upregulate the expression or activity of SIRPα or its interaction with CD47.

公开(公告)号：US20210155902A1

公开(公告)日：2021-05-27

申请号：US16610624

申请日：2018-05-04

申请人： MEDIZINISCHE HOCHSCHULE HANNOVER

发明人： Nico LACHMANN ,  Mania ACKERMANN ,  Henning KEMPF ,  Robert ZWEIGERDT ,  Thomas MORITZ

IPC分类号： C12N5/0786 ,  C12N5/0787 ,  C12N5/078 ,  A61K35/15 ,  A61K35/18 ,  A61K35/19 ,  A61P31/04 ,  C12P21/00

摘要： The present invention relates to stem-cell derived hematopoietic cells, in particular, myeloid cells, preferably, macrophages, their generation and use. In particular, the invention relates to a method of producing hematopoietic, preferably, myeloid cells, comprising cultivating embryoid bodies, which are, e.g., derivable from pluripotent stem cells such as induced pluripotent stem cells (iPSC), in suspension culture, to produce myeloid cell forming complexes, which are further cultivated in suspension culture to produce myeloid cells such as macrophages. This allows for a scalable and continuous production, e.g., in industry-compatible stirred tank bioreactors. Macrophages, e.g., macrophages produced with this method that have unique characteristics, can be used in pharmaceutical compositions for treatment of patients, e.g., for treatment of infection such as bacterial infection. The invention further provides application systems suitable for spraying, comprising myeloid cells such as macrophages, which can have a reduced size, for use in treatment of patients for treatment of infection, e.g., bacterial infection or wound healing.

公开(公告)号：US20210154281A1

公开(公告)日：2021-05-27

申请号：US17033050

申请日：2020-09-25

申请人： Massachusetts Institute of Technology

发明人： Darrell Irvine ,  Michael Yaffe ,  Ganapathy Sriram ,  Lauren Milling

IPC分类号： A61K39/00 ,  A61K35/15 ,  A61K35/17 ,  A61K45/06 ,  G01N33/50

摘要： Described are cell-based cancer vaccines and anti-cancer immunotherapies. The vaccines include isolated tumor cells activated with one or more genotoxic drugs, and, optionally, treated with one or more MK2 inhibitors. The activated cells are highly immunogenic non-proliferative cells, and may be tested for immunogenicity ex vivo for priming T cells by co-incubating the isolated activated cells with dendritic cells and T cells. The vaccines are typically administered into patient's tumor to provide an intratumoral immune activation. Immune checkpoint inhibitor(s) (ICI) may be administered before, during, or after vaccine administration. ICI may be a component of the vaccine. The vaccines confer heightened cytotoxic immune response against the cancer cells, induce tumor regression, and enhance survival from cancer. The vaccines prevent tumor recurrence and induce a long-lasting anti-tumor immunological memory.

公开(公告)号：US11013764B2

公开(公告)日：2021-05-25

申请号：US16827302

申请日：2020-03-23

申请人： Myeloid Therapeutics, Inc.

发明人： Daniel Getts ,  Yuxiao Wang

IPC分类号： A61K35/15 ,  C07K14/705 ,  A61P35/00 ,  C07K16/28

摘要： The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.

公开(公告)号：US20210128611A1

公开(公告)日：2021-05-06

申请号：US16487259

申请日：2017-07-25

申请人： Cellular Approaches, Inc.

发明人： Court TURNER

IPC分类号： A61K35/15 ,  A61K35/51 ,  A61K45/06 ,  C12N5/0786 ,  A61P31/04

摘要： Provided herein are innate immune cells for use in therapeutic methods. Also described herein are pharmaceutical compositions comprising innate immune cells for use in the treatment of a variety of diseases including, but not limited to pathogenic infections, pulmonary diseases, inflammatory diseases, autoimmune diseases, and immunodeficiency.

公开(公告)号：US20210113611A1

公开(公告)日：2021-04-22

申请号：US16965816

申请日：2019-01-31

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Benjamin M. Segal ,  Andrew Sas ,  Kevin Carbajal

IPC分类号： A61K35/15 ,  C12N5/0787

摘要： Provided herein are compositions and methods for treating neurological disorders. In particular, provided herein are neutrophils that rescue damaged neurons, methods of making such neutrophils, and methods of promoting generation of such neutrophils in vivo.

公开(公告)号：US20210077533A9

公开(公告)日：2021-03-18

申请号：US14599641

申请日：2015-01-19

申请人： Reapplix ApS

发明人： Rasmus LUNDQUIST ,  Niels Erik HOLM

IPC分类号： A61K35/19 ,  A61K35/33 ,  A61K38/36 ,  A61K35/15 ,  C12N5/078 ,  C12N5/0787

摘要： A blood product (10), a method for preparing the blood product, a blood product obtainable by the method and a blood product preparing container means. The blood product comprises components from whole blood, especially fibrin, thrombocytes and leukocytes. The blood product (10) comprises a first layer (21), a second layer (22) and a third layer (23). The second layer (22) is adjacent to the first layer (21) and the third layer (23). The first layer (21) defines a first outer surface (24) of the blood product (10) and the third layer (23) defining a second outer surface (25) of the blood product (10). The first layer (21) comprises a majority of fibrin, the second layer (22) comprises a majority of thrombocytes and the third layer (23) comprises a majority of leukocytes.

公开(公告)号：US20210059962A1

公开(公告)日：2021-03-04

申请号：US17010720

申请日：2020-09-02

申请人： Regen Biopharma, Inc.

发明人： Thomas Ichim ,  David Koos

IPC分类号： A61K31/05 ,  C07K16/28 ,  A61K38/20 ,  A61K35/15 ,  A61K35/28 ,  A61P19/02

摘要： Disclosed are means, methods, and compositions of matter for stimulation of T regulatory (Treg) cells by cannabidiol. In one embodiment, administration of cannabidiol is performed in an animal suffering from autoimmunity. In situations of autoimmunity, cannabidiol induces generation of Treg cells while other agents or therapies may be used to expand such cells in vitro and/or in vivo. In some embodiments the administration of cannabidiol is performed together with agents such as low dose interleukin-2 in order to treat inflammatory conditions such as arthritis or other conditions associated with reduction in Treg cells such as pregnancy failure, type 1 diabetes, or graft versus host disease.

公开(公告)号：US10933095B2

公开(公告)日：2021-03-02

申请号：US14599641

申请日：2015-01-19

申请人： Reapplix ApS

发明人： Rasmus Lundquist ,  Niels Erik Holm

IPC分类号： A61K35/19 ,  A61K38/36 ,  A61K38/17 ,  A61K38/15 ,  A61K35/33 ,  A61K35/15 ,  A61L24/10 ,  B04B5/04 ,  C12N5/0787 ,  C12N5/078 ,  A61L26/00

摘要： A blood product (10), a method for preparing the blood product, a blood product obtainable by the method and a blood product preparing container means. The blood product comprises components from whole blood, especially fibrin, thrombocytes and leukocytes. The blood product (10) comprises a first layer (21), a second layer (22) and a third layer (23). The second layer (22) is adjacent to the first layer (21) and the third layer (23). The first layer (21) defines a first outer surface (24) of the blood product (10) and the third layer (23) defining a second outer surface (25) of the blood product (10). The first layer (21) comprises a majority of fibrin, the second layer (22) comprises a majority of thrombocytes and the third layer (23) comprises a majority of leukocytes.